The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| RGNX | +30.84% | -78.98% | -26.77% | -72% |
| S&P | +20.12% | +68.19% | +10.95% | +233% |
Regenxbio is the expert in adeno-associated virus (AAV) delivery of potentially curative gene therapies through its NAV technology platform.
The company focuses on using its technology for gene-editing therapies.
Now is a good time to take a closer look at these stocks.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $30.34M | 43.0% |
| Gross Profit | $20.54M | 88.9% |
| Gross Margin | 67.71% | 16.5% |
| Market Cap | $728.97M | 90.3% |
| Market Cap / Employee | $1.96M | 0.0% |
| Employees | 371 | 5.1% |
| Net Income | -$67,149.00K | -31.2% |
| EBITDA | -$53,767.00K | -13.6% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $34.47M | -40.1% |
| Accounts Receivable | $26.38M | 28.8% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $212.62M | 113.7% |
| Short Term Debt | $47.90M | 13.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.19% | 1.5% |
| Return On Invested Capital | -37.25% | -8.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$52,798.00K | -61.4% |
| Operating Free Cash Flow | -$52,290.00K | -65.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.36 | 1.50 | 2.28 | 4.51 | 255.40% |
| Price to Sales | 2.35 | 2.71 | 3.09 | 4.37 | -4.88% |
| Price to Tangible Book Value | 1.36 | 1.50 | 2.28 | 4.51 | 255.40% |
| Enterprise Value to EBITDA | 14.51 | -6.25 | -10.15 | -14.43 | 135.49% |
| Return on Equity | -47.4% | -62.5% | -76.9% | -107.0% | 34.61% |
| Total Debt | $133.53M | $271.69M | $268.14M | $260.52M | 83.83% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
